Shots:
- The GATHER1 & GATHER2 studies assessed Izervay (QM) vs sham in pts with GA secondary to AMD for 18 & 12mos., respectively, where in GATHER2, pts were later re-randomized to Izervay QM or Q2M for 24mos.
- In the driving-eligible pts (BCVA of ≥70 ETDRS letters; n=403), Izervay reduced the risk of losing driving eligibility to 12.6% vs 20.1% with sham, reflecting a 41% relative risk reduction; Similar benefits were observed after switching from QM to Q2M dosing. QM-only dosing showed a 35% relative risk reduction (15.1% vs 20.1%)
- Exploratory long-term GATHER2 OLE data showed sustained slowing of GA lesion growth, with earlier treatment providing greater retinal tissue preservation; GA lesion growth from mos. 24-42 was reduced by 40.5% vs projected sham in pts switched to QM from QM or Q2M & by 37% in prior sham-treated pts receiving Izervay QM
Ref: PRnewswire | Image: Astellas | Press Release
Related News: Astellas Exercises Option to License Dyno’s AAV Capsid for AI-Designed Gene Delivery
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
